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Nearly racemic ketoprofen, which satisfies the requirements 
for the occurrence of preferential enrichment, was 
spontaneously resolved into the two enantiomers by simple 10 
crystallization under nonequilibrium conditions using high 
concentrations. 
In connection with the industrial and pharmaceutical needs of 
chiral organic substances, exploitation of economically and 
environmentally acceptable enantiomeric resolution methods 15 
along with catalytic asymmetric syntheses has been the subject of 
considerable recent development. In this context, spontaneous 
resolution of racemic compound crystals, which are composed of 
a regular packing of a pair of R and S enantiomers in the crystal, 
by simple crystallization from solvents had been believed to 20 
never occur for more than a century.1 However, recently we 
reported that preferential enrichment, a spontaneous resolution 
phenomenon observed for a certain kind of racemic mixed 
crystals (or solid solutions) consisting of a random arrangement 
of two enantiomers in the crystal,2,3 was applicable to two amino 25 
acids (alanine and leucine) and the cocrystal of (DL)-
phenylalanine with fumaric acid,4,5 which are classified as a 
racemic compound with a high eutectic ee value6 and at the same 
time display an appropriate polymorphic transition during 
crystallization under nonequilibrium conditions using high 30 
concentrations. 
To extend the scope of preferential enrichment to 
pharmaceutically relevant compounds, we have carried out an 
extensive search in the Cambridge Structural Database (CSD) for 
chiral drugs with an appropriate crystal structure for exhibiting 35 
preferential enrichment. Consequently, we have found that 
nonsteroidal anti-inflammatory drugs (NSAID) such as ibuprofen 
(space group, P21/c),
7 ketoprofen (P-1),8 and naproxen (Pbca),9  
which are popular therapeutic agents for the treatment of various 
pathophysiological conditions, have the desired racemic crystal 40 
structure containing heterochiral RS dimer chains as well as 
homochiral 1D R and S chains. Among them, only ketoprofen 
satisfied all the five requirements for the occurrence of 
preferential enrichment which we have clarified thus far; (1) high 
eutectic ee value, (2) sufficient solubility difference (pure 45 
enantiomer >> racemate), (3) unique crystal structure and 
polymorphic transition, (4) partial crystal disintegration, and (5) 
deposition of nonracemic mixed crystals.2-5 No polymorphic 
transition was observed during crystallization for ibuprofen and 
naproxen. Indeed, only ketoprofen showed a good preferential 50 
enrichment phenomenon, despite a single-component crystal.2 
Ketoprofen is currently marketed as the racemic drug. However, 
Fig. 1 Preferential enrichment of ketoprofen. Conditions: aH2O- 
EtOH (v/v 1:1, 3.7 mL) at –16°C for 4 days; bH2O-EtOH (v/v 1:1, 
2.8 mL) at –16°C for 4 days; cH2O-EtOH, (v/v 1:1, 2.4 mL) at –16°C 
for 4 days; dH2O-EtOH (v/v 1:1, 2.2 mL) at –16°C for 4days;
 
eremoval of the solvent by evaporation. The ee values were 
determined by HPLC analysis (see Figure S1). 
Fig. 2  Relation between the ee values of S-rich ketoprofen in the ca. 10-
fold supersaturated solutions (horizontal axis) before crystallization and 
the chirality and reached ee values in the deposited crystals (left vertical 
axis) and in solution (right vertical axis) after crystallization. 
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the biological activity resides in the S enantiomer, while the R 
enantiomer is therapeutically inactive.10 Furthermore, it is known 
that there is no significant enantiomeric inversion of R to S in 
humans.11 Here we report the preferential enrichment 
phenomenon of nearly racemic ketoprofen which can behave like 5 
the desired racemic mixed crystal showing an appropriate 
polymorphism and allowing the deposition of nonracemic 
crystals under nonequilibrium preferential enrichment conditions.  
By considering the physicochemical properties of ketoprofen  
(solubility: 57.8 and 31.1 mg/mL for the S enantiomer and 10 
racemate, respectively, at 25°C in H2O-EtOH (v/v 1:0.9)) and its 
binary and ternary phase diagrams (eutectic point: 82% ee),10 we 
determined the optimum preferential enrichment conditions. 
Namely, when crystallization was carried out from the 10-fold 
supersaturated H2O-EtOH (v/v 1:1) solution of nonracemic 15 
ketoprofen of more than 1% ee (e.g., S-rich) at –16°C, the excess 
S enantiomer was enriched in the mother liquor until the 
deposited crystals were slightly enriched with the opposite R 
enantiomer (Figure 1), which is characteristic of the preferential 
enrichment phenomenon.2 The ee of S enantiomer in the mother 20 
liquor after crystallization rose nonlinearly with increasing ee of 
S enantiomer in the initial supersaturated solutions, while the ee 
of R enantiomer in the deposited crystals reached a plateau at 
around 1.5 % ee (Figure 2). Similar results were obtained when 
crystallization was performed by using R-rich crystals of more 25 
than 1 % ee. Thus, repetition of recrystallization of each crop of 
resulting deposited crystals successively from the supersaturated 
solution without stirring led regularly to not only an alternating 
enrichment of the two enantiomers up to 68% ee in the mother 
liquors but also a slight enrichment (ca. 1.5% ee) of the opposite 30 
enantiomer in the deposited crystals (Figure 1). 
As a practical enantiomeric resolution technique of 
ketoprofen, the subsequent recrystallization of the resulting 
enantioenriched crystals (~68% ee) from ether under the 
conditions for depositing racemic compound crystals improved 35 
the ee values of R and S enantiomers up to more than 90 % in the 
mother liquors. 
The crystal structure of (RS)-ketoprofen analyzed by us was 
identical to that retrieved from CSD (Figure 3 and S2).8 
Molecules of ketoprofen form homochiral 1D R and S chains 40 
along the c-axis through (i) an intermolecular C(sp2)-H···O=C 
(2.66 Å) hydrogen bond [Graph set: C(6)]11 between a phenyl 
hydrogen atom and a carboxyl oxygen atom and (ii) another 
intermolecular C(sp2)-H···O=C (2.71 Å) hydrogen bond [C(5)] 
between a hydrogen atom on another benzene ring and the 45 
neighboring keto carbonyl oxygen atom. Such adjacent 
antiparallel homochiral 1D R and S chains constitute a 
heterochiral RS dimer chain structure along the c-axis by the 
formation of a cyclic dimer structure through conventional O-
H···O=C (O···O: 2.63 Å) hydrogen bonds [R22(8)] between 50 
neighboring two carboxyl groups. These heterochiral RS dimer 
chains interact with each other by off-centered centrosymmetric 
C-H--- contact between the hydrogen atom on the chiral carbon 
atom and the neighboring phenyl ring along the b-axis (Figure 
3b), creating a loosely packed crystal structure which can allow 55 
the partial crystal disintegration to occur in case irregular 
molecular alignment areas are formed in the crystal lattice under 
kinetic crystallization conditions (see Figure 5). 
The powder X-ray diffraction pattern simulated from the X-
ray crystallographic data of the single crystal of (RS)-ketoprofen 60 
was identical with the experimental pattern of the fine 
polycrystalline powder sample of the deposited nonracemic 
crystals of 1.2% ee obtained by the preferential enrichment 
experiment (Figure 4a). Furthermore, DSC analyses of the RS 
crystals and the deposited crystals of 1.2% ee showed a sharp 65 
endothermic peak at 96.7 and 96.1 °C, respectively, which were 
higher than that (77.6°C) of the pure S enantiomer (Figure 4b). 
These experimental results strongly suggest that (i) the deposited 
crystals of 1.2% ee are monophasic and (ii) they are neither a 
conglomerate nor a chiral lamellar twin of opposite handedness 70 
but either a racemic mixed crystal of two enantiomers or an 
achiral lamellar twin of racemic compound type.5,6 By SEM 
observation of the deposited crystals, no thin plate form crystal 
characteristic of an achiral lamellar twin crystal was detected, but 
instead very fine polycrystals with irregular bumpy surfaces 75 
which were reminiscent of considerable crystal disintegration 
were observed (Figure S3).4,5 Thus, from these results and X-ray 
crystallographic analyses, the deposition of nonracemic mixed 
crystals under the preferential enrichment conditions was strongly 
supported. 80 
To propose the mechanism of preferential enrichment of 
ketoprofen, the association modes of enantiomers in the 
supersaturated solution just before crystallization and in the 
deposited crystals after crystallization were compared. The 
distinct difference in the in situ ATR-IR spectra between the 85 
supersaturated solution and the deposited crystals (Figure S4) 
suggested the occurrence of polymorphic transition during 
crystallization.2-5 Based on this observation and the crystal 
structure of deposited crystals, together with the thus far proposed 
mechanism of preferential enrichment,2-5 the observed 90 
preferential enrichment phenomenon of ketoprofen can be 
interpreted in terms of the following successive processes  (in 
case of using a slightly S-rich sample) (Figure 5a) : (i) 
preferential formation of homochiral 1D R and S chains in the 
slightly S-rich solution, (ii) a solid-to-solid polymorphic 95 
transition of the metastable, slightly S-rich mixed crystals 
composed of the same homochiral R and S chains into the stable, 
slightly S-rich mixed crystals mainly composed of heterochiral 
cyclic dimer chains, and (iii) partial crystal disintegration in the 
irregular molecular alignment area, where an even number of 100 
Fig. 3 Crystal structure of (RS)-ketoprofen. (a) A view down the b-
axis. (b) A view down the c-axis. See Figure S2 for a view down the a-
axis. 
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homochiral S chains (four in this case) are surrounded by two R 
chains before polymorphic transition inside the transformed 
crystal lattice to selectively release the excess S enantiomer into 
solution until the deposited crystals are slightly enriched with the 
opposite R enantiomer (ca.1% ee), resulting in the generation of 5 
crystal defects incapable of undergoing crystal growth any longer 
(Figure S3). This crystal disintegration should occur at the 
incomplete dimer sites due to the presence of a weakened 
hydrogen bond between two carboxyl groups (O···O: 4.33 and 
7.24 Å for S’-S and S’-R’ dimers, respectively, vs 2.63 Å for R-S 10 
cyclic dimer), which arises from the positional disorder of the 
two enantiomers (Figure 5b).  
Conclusions 
We have demonstrated that nearly racemic ketoprofen can behave 
like a racemic mixed crystal showing polymorphic transition and 15 
allowing the deposition of nonracemic crystals under 
nonequilibrium crystallization conditions, eventually leading to 
the occurrence of preferential enrichment, despite a single-
component crystal. This result strongly supports the propriety of 
our proposed mechanism and five requirements with respect to 20 
preferential enrichment. We believe that preferential enrichment 
should become a potent enantiomeric resolution method for a lot 
of racemic compound crystals, together with the further 
development of nonequilibirum crystallization technologies. 
 25 
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Fig. 4 Comparison of crystal properties between (RS)-ketoprofen and 
deposited crystals (1.2% ee, S-rich) after recrystallization. (a) X-ray 
powder diffraction pattern simulated from the X-ray crystallographic data 
of (RS)-ketoprofen (up) and experimental pattern of the deposited (S)-rich 
crystals (down). (b) DSC profiles of (RS)- and (S)-ketoprofen, and the 
deposited (S)-rich crystals. 
Fig. 5 The proposed mode of polymorphic transition of 
nonracemic  ketoprofen. (a) Transformation of a metastable form 
into a stable one. (b) Hypothetical cyclic dimer structure in the 
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